There has been growing evidence that various biomarkers such as PD-L1 expression, tumor mutational burden (TMB), defective DNA mismatch repair (dMMR), microsatellite instability (MSI), tumor microenvironment (TME), and microbiota are associated with altered immunotherapy outcomes. The gene discussed is CD274; the disease is neoplasm.